Arash Ghodousi

Dr. Arash Ghodousi

Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infec-tious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2023 in Breathe
Verified
Journal Article
Open access
PDF file
RVRaquel Villar-Hernández
Raquel Villar-Hernández
AGArash Ghodousi
Arash Ghodousi
OKOlha Konstantynovska
Olha Konstantynovska
RDRaquel Duarte
Raquel Duarte
CLChristoph Lange
Christoph Lange
MRMario Raviglione
Mario Raviglione
Despite being a preventable and curable disease, tuberculosis (TB) is still a major global health threat and the second leading cause of death due to an infectious agent worldwide. All the efforts invested to end TB have resulted overall in rather slow decreases in TB incidence and mortality rates, which have been further negatively affected by the ongoing coronavirus disease 2019 (COVID-19) pandemic. While the majority of targets of the End TB Strategy remain off track, and we have not yet overcome the disruptions caused by the COVID-19 pandemic, recent conflicts such as the ongoing war in Ukraine are threatening the decrease of the burden of TB even further. To get back on track and get closer to ending TB, we need urgent, global, well-structured and committed multi-sectoral actions that go beyond national and global TB programmes with the support of deep investments in research and facilitation of equitable and rapid implementation of innovation worldwide.

1 September 2018 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
RMReza Mirnejad
Reza Mirnejad
AAArezoo Asadi
Arezoo Asadi
SKSaeed Khoshnood
Saeed Khoshnood
HMHabibollah Mirzaei
Habibollah Mirzaei
MHMohsen Heidary
Mohsen Heidary
DDDavood Darban-Sarokhalil
Davood Darban-Sarokhalil

1 November 2019 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
MHMohsen Heidary
Mohsen Heidary
SBSaeed Zaker Bostanabad
Saeed Zaker Bostanabad
SASeyed Mohammad Amini
Seyed Mohammad Amini
AJAlireza Jafari
Alireza Jafari
MNMostafa Ghalami Nobar
Mostafa Ghalami Nobar
DDDavood Darban-Sarokhalil
Davood Darban-Sarokhalil
Background: Nowadays, tuberculosis (TB) is one of the top ten leading causes of mortality worldwide. The emergence of multidrug-resistant (MDR) – and extensively drug-resistant (XDR) – Mycobacterium tuberculosis (M. tuberculosis) is identified as one of the most challenging threats to TB control. Thus, new and safe nano-drugs are urgently required for the elimination of TB. The aim of this study was to investigate the anti-bacterial effects of Ag, ZnO, and Ag-ZnO nanoparticles (NPs) on MDR- and XDR-M. tuberculosis. Materials and methods: In this study, Ag, ZnO, and Ag-ZnO NPs were synthesized by the chemical reduction and chemical deposition methods. NPs were characterized using ultraviolet–visible spectroscopy, dynamic light scattering, and transmission electron microscopy. Then, various dilutions of NPs were prepared and their minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) were determined against M. tuberculosis strains using the broth microdilution and agar microdilution methods. Finally, MTT test and cell culture assay were performed. Results: The effects of concentrations of 1–128 μg/mL Ag NPs, ZnO NPs, 2Ag: 8ZnO, 8Ag:2ZnO, 3Ag: 7ZnO, 7Ag:3ZnO, and 5Ag:5ZnO on M. tuberculosis strains were investigated. MIC results showed the inhibitory effect of 1 μg/mL of all NPs against XDR-M. tuberculosis. In addition, the concentrations of 4 μg/mL Ag, 8 μg/mL 5Ag:5ZnO, 8 μg/mL 7Ag:3ZnO, 32 μg/mL 3Ag:7ZnO, 16 μg/mL 8Ag:2ZnO, and 64 μg/mL 2Ag:8ZnO inhibited MDR-M. tuberculosis growth. However, MBC results indicated the inability of Ag, ZnO and Ag-ZnO NPs, either in combination or alone, to kill MDR- or XDR-M. tuberculosis. Conclusion: To the best of our knowledge, this is the first study to evaluate the effects of Ag and ZnO NPs against MDR and XDR strains of M. tuberculosis. According to the results, Ag and ZnO NPs showed bacteriostatic effects against drug-resistant strains of M. tuberculosis. Therefore, these NPs may be considered as promising anti-mycobacterial nano-drugs. However, further studies are required to affirm the bactericidal effects of these NPs against TB.

1 September 2019 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
AGArash Ghodousi
Arash Ghodousi
ARAlamdar Hussain Rizvi
Alamdar Hussain Rizvi
ABAurangzaib Quadir Baloch
Aurangzaib Quadir Baloch
AGAbdul Ghafoor
Abdul Ghafoor
FKFaisal Masood Khanzada
Faisal Masood Khanzada
DCDaniela Cirillo
Daniela Cirillo
We report on the first six cases of acquired resistance to bedaquiline in Pakistan. Seventy sequential isolates from 30 drug-resistant-tuberculosis patients on bedaquiline-containing regimens were retrospectively tested for bedaquiline resistance by MIC testing and by the detection of mutations in relevant genes. We documented cases failing therapy that developed specific mutations in Rv0678 and had increased MICs associated with cross-resistance to clofazimine during treatment.

1 July 2015 in Foodborne Pathogens and Disease
Verified
Journal Article
Closed access
AGArash Ghodousi
Arash Ghodousi
CBCelestino Bonura
Celestino Bonura
ANAnna Maria Di Noto
Anna Maria Di Noto
CMCaterina Mammina
Caterina Mammina
Globally, antimicrobial drug-resistant Escherichia coli is among the most common etiological agents of invasive disease in humans. In Europe, increasing proportions of infections due to third-generation cephalosporins and/or fluoroquinolone-resistant extraintestinal pathogenic E. coli (ExPEC) strains are reported. E. coli from poultry are those more closely linked to human E. coli, but lack of reliable data makes it difficult to assess the attributable risk of different food sources. In the present study, our objective was to investigate the antimicrobial resistance profile, phylogenetic background, and virulence factors of E. coli isolates from broiler chicken meat sold at retail in Palermo, Italy. Isolation of multidrug resistant (MDR) E. coli was performed during April-December 2013 on a total of 163 chicken meat samples. Susceptibility to a panel of nine antimicrobial agents was determined. PCR assays were carried out to detect extended-spectrum β-lactamase (ESBL), plasmid-mediated AmpC β-lactamase, and plasmid-mediated quinolone resistance (PMQR) genes, phylogenetic group, and ExPEC-associated traits. A single nucleotide polymorphism (SNP) PCR was done to detect E. coli sequence type (ST)131. One hundred thirty-four isolates from 109 meat samples were MDR. B1 was the most prevalent phylogenetic group (47.8%), followed by groups D (25.4%), A (22.3%), and B2 (4.5%). ESBLs and AmpC β-lactamases were detected by PCR in 132 (98.5%) and 15 (11.2%) isolates. PMQR determinants were detected in 122 (91%) isolates. Twenty-two MDR isolates met the molecular definition of ExPEC. SNP-PCR results confirmed that four B2 isolates were ST131. Enterobacterial Repetitive Intergenic Consensus sequence-PCR analysis showed a large heterogeneity with 55 unique profiles and 31 clusters including 2-4 isolates. An alarmingly high prevalence of MDR E. coli from broiler chicken meat is evident in our geographic area. The ongoing use of antimicrobial drugs in livestock should be urgently restricted, particularly in the poultry sector.

1 July 2019 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
AGArash Ghodousi
Arash Ghodousi
ETElisa Tagliani
Elisa Tagliani
EKEranga Karunaratne
Eranga Karunaratne
Stefan NiemannStefan Niemann
Stefan Niemann
JPJennifer Perera
Jennifer Perera
DCDaniela Cirillo
Daniela Cirillo
MIC testing using the Bactec mycobacteria growth indicator tube system 960 of 70 phylogenetically diverse, isoniazid-resistant clinical strains of Mycobacterium tuberculosis revealed a complex pattern of overlapping MIC distributions. Whole-genome sequencing explained most of the levels of resistance observed. The MIC distribution of strains with only inhA promoter mutations was split by the current concentration endorsed by the Clinical and Laboratory Standards Institute to detect low-level resistance to isoniazid and is, consequently, likely not optimally set.